genetic knockout
B2M Knockout THP-1 Cell Line |
|||
78389 | BPS Bioscience | 2 vials | 6500 EUR |
Description: B2M (Beta-2-Microglobulin) has been genetically removed by CRISPR/Cas9 genome editing from THP-1 cells. |
|||
CIITA Knockout THP-1 Cell Line |
|||
78390 | BPS Bioscience | 2 vials | 6500 EUR |
Description: CIITA (Class II Transactivator) has been genetically removed from THP-1 cells using CRISPR/Cas9 genome editing. |
|||
FCGR2A (CD32A) Knockout Jurkat Cell Line |
|||
78549 | BPS Bioscience | 2 vials | 6500 EUR |
Description: The FCGR2A Knockout Jurkat cell line was generated by CRISPR/Cas9 genome editing to remove FCGR2A (CD32A), the gene encoding protein FcγRIIa (Fragment crystallizable gamma receptor II a, also known as FcGRIIa, Fc-gamma-RIIa, and CD32A). |
|||
TCR/B2M Knockout Jurkat Cell Line |
|||
78552 | BPS Bioscience | 2 vials | 8645 EUR |
Description: This cell line is a double knockout of TCR (T Cell Receptor) and B2M (Beta-2-Microglobulin). First, the TRAC (T-Cell Receptor Alpha Constant) and the TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from Jurkat cells to generate the TCR Knockout Jurkat cell Line (BPS Bioscience #78539). These TCR knockout cells were then used to generate a new cell line in which B2M was also genetically removed by CRISPR/Cas9 genome editing. |
|||
Human Genetic suppressor element 1, GSE1 ELISA KIT |
|||
ELI-27963h | Lifescience Market | 96 Tests | 988.8 EUR |
Mouse Genetic suppressor element 1, Gse1 ELISA KIT |
|||
ELI-48300m | Lifescience Market | 96 Tests | 1038 EUR |
B2M Knockout NFAT Luciferase Reporter Jurkat Cell Line |
|||
78363 | BPS Bioscience | 2 vials | 11095 EUR |
Description: B2M (Beta-2-Microglobulin) has been genetically removed by CRISPR/Cas9 genome editing from NFAT Luciferase Reporter Jurkat cells. Expression of the firefly luciferase gene is driven by NFAT response elements located upstream of the minimal TATA promoter. Activation of the NFAT signaling pathway in these cells can be monitored by measuring luciferase activity. |
|||
B2M/CIITA Double Knockout THP-1 Cell Line |
|||
78391 | BPS Bioscience | 2 vials | 9500 EUR |
Description: Both B2M (Beta-2-Microglobulin) and CIITA (Class II Transactivator) have been genetically removed from THP-1 cells using CRISPR/Cas9 genome editing. |
|||
CRISPR/Cas9 Kinase Knockout Lentivirus Library (Array Format) |
|||
78487 | BPS Bioscience | 200 µl x 649 | 7700 EUR |
Description: The CRISPR/Cas9 Kinase Knockout Lentivirus Library (Array Format) targets 619 human kinases and pseudo-kinases.bpsbioscience.com/media/wysiwyg/Kinases/Kinase_Library_-_List_Kinases_Pseudokinases_06-15-2022.xlsx Download the table to view all available kinases. The Array consists of a series of vials, with each vial containing a mixture of integrating CRISPR/Cas9 lentiviral particles targeting 5 sgRNAs for a specific gene (1 vial per gene, 5 sgRNAs per gene). The Array also includes a total of 150 control sgRNAs that do not target any gene (combined into 30 vials containing 5 control sgRNAs per vial). Thus, the Array contains a total of 649 vials and 3,245 sgRNAs.The lentiviruses are replication incompetent, VSV-G pseudotyped lentiviral particles ready to infect almost all types of mammalian cells, including primary and non-dividing cells. The SIN (self-inactivation) lentiviral backbone contains the Cas9 gene (Streptococcus pyogenes CRISPR associated protein 9) driven by an EF1a promoter, an sgRNA driven by a U6 promoter, and a puromycin selection marker.The lentiviruses integrate randomly into the cellular genome to express both Cas9 and the sgRNAs. Because the lentiviruses contain Cas9, they can be used in any target cell regardless of whether the cells already express Cas9. Puromycin selection ensures high expression of both Cas9 and the sgRNAs. Knockout efficiencies will depend on the cell type and the gene of interest. Stable CRISPR/Cas9 knockout cell lines can also be generated following limiting dilution.The library is delivered with a User Manual booklet. |
|||
TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line |
|||
78556 | BPS Bioscience | 2 vials | 12205 EUR |
Description: This cell line is a knockout of TCR (T Cell Receptor). The TRAC (T-Cell Receptor Alpha Constant) and TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from recombinant Jurkat cells stably expressing the firefly luciferase gene under the control of NFAT response elements.This cell line has been functionally validated and does not respond to anti-CD3 agonist antibodies, as opposed to parental NFAT-Luciferase Reporter Jurkat cells (BPS Bioscience #60621). |
|||
TCR/B2M Knockout NFAT Luciferase Reporter Jurkat Cell Line |
|||
78557 | BPS Bioscience | 2 vials | 16695 EUR |
Description: This cell line is a double knockout of TCR (T Cell Receptor) and B2M (Beta-2-Microglobulin). First, the TRAC (T-Cell Receptor Alpha Constant) and the TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from NFAT Luciferase Reporter Jurkat cells to generate the TCR Knockout NFAT Luciferase Reporter Jurkat cell Line (BPS Bioscience #78556). These TCR knockout cells were used to generate a new cell line in which B2M was also genetically removed by CRISPR/Cas9 genome editing. _x000D_Expression of the firefly luciferase gene is driven by NFAT response elements located upstream of the minimal TATA promoter. Activation of the NFAT signaling pathway in these cells can be monitored by measuring luciferase activity. |